Navigation Links
Reportlinker Adds Boehringer Ingelheim GmbH: PharmaVitae Profile
Date:12/15/2009

NEW YORK, Dec. 15 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Boehringer Ingelheim GmbH: PharmaVitae Profile

http://www.reportlinker.com/p0168539/Boehringer-Ingelheim-GmbH-PharmaVitae-Profile.html

Introduction

This analysis examines the historical and forecast performance for Boehringer Ingelheim in the Rx pharmaceutical sector. The profile encompasses company strategy, portfolio and pipeline analysis and assessment of financial performance, with 1-6 year sales forecasts for key drugs. An interactive forecasting and analysis tool provides continually updated quantitative and qualitative information.

Reasons to Purchase

*Benchmark Boehringer Ingelheim's performance against key rivals in the prescription pharmaceutical sector

*Evaluate the impact of upcoming patent expiries for Flomax and Sifrol on the company's outlook

*Track the progress of key new launches including Pradaxa and Ondero, upon which the company is highly reliant

ABOUT DATAMONITOR HEALTHCARE 2

About the PharmaVitae team 2

Chapter 1 About this profile 3

PharmaVitae Explorer database 3

Chapter structure 3

Executive summary 3

Quarterly news update 3

Company introduction 3

Company sales 4

Company financials 4

Key products and competitors 4

Data sourcing 4

Sales data 4

Analyst consensus 4

Chapter 2 Executive summary 5

Key findings 5

Prescription pharmaceutical sales and growth rate performance, 2002-14 6

Financial performance, 2002-14 7

Boehringer Ingelheim: PharmaVitae forecasts at a glance 8

Strategic insight 9

Leading position in core markets 9

Focused therapeutic coverage following key successes 9

Specialization can restrict opportunities 10

New launches struggle to match the decline of existing products 11

Drag on growth as historical drivers turn to decline 11

Decline highlights challenges beyond 2014 12

External product deals needed to extend growth 12

Historical reliance upon internal discoveries 12

Tougher competition for late-stage product deals 13

SWOT analysis 14

Strengths 14

Weaknesses 16

Opportunities 16

Threats 17

TABLE OF CONTENTS 19

TABLE OF FIGURES 21

Chapter 3 Quarterly news update 22

Key findings 22

Product developments 23

Deals and alliances 25

Product deals 25

Technology deals 26

M&A activity 26

Company announcements 27

Future product milestones 28

Chapter 4 Company introduction 29

Key findings 29

Background 30

M&A history 30

Current corporate structure 31

Prescription Pharmaceuticals 32

Consumer Health Care 33

Industrial Customer 33

Animal Health 34

Chapter 5 Company sales 35

Key findings 35

Prescription pharmaceutical sales and growth rate analysis, 2002-14 36

Product analysis 38

Product analysis, 2002-08 39

Product analysis, 2008-14 42

Therapy area analysis 47

Geographic analysis 51

Launch/core/expiry analysis 54

Explanation of launch/core/expiry analysis 54

Launch analysis, 2008-14 55

Core analysis, 2008-14 58

Expiry analysis, 2008-14 59

Generics analysis, 2008-14 61

Launch/core/expiry configuration, 2008-14 62

Molecule type analysis 64

Externalization analysis 67

Chapter 6 Company financials 70

Key findings 70

Reconciliation between PharmaVitae-formatted prescription pharma sales and company-reported total sales, 2002-08 71

Operating costs and profit analysis 73

Operating costs and profit analysis, 2002-08 74

Operating cost ratio and profit margin analysis, 2002-08 75

Operating cost ratio and profit margin analysis, 2008-14 76

Operating costs and profit analysis, 2008-14 76

Chapter 7 Key products and competitors 77

Key findings 77

Overview 78

Respiratory 79

Spiriva franchise 79

Overview 79

Sales forecast 80

Success driven by unique market position 80

Spiriva's position strengthened by novel delivery device 81

Competing LAMAs delayed until 2012 in the US 82

Combination set to extend Spiriva franchise, but will not maintain growth 82

Cardiovascular 84

Micardis franchise 84

Overview 84

Sales forecast 85

Uptake driven by best in class attributes 85

Growth maintained despite competition across 2008-14 86

Lifecycle management strengthens franchise 86

Pradaxa 88

Overview 88

Sales forecast 89

Uptake driven by unmet need 89

Pradaxa may be adversely affected by DTI history 90

Competition will prevent greater capture of market share 90

Trial program designed to allow label expansion 91

Endocrine, metabolic & genetic disorders 92

Ondero (BI 1356) 92

Overview 92

Sales forecast 93

Expected to be the third DPP-IV inhibitor to market in the US 93

Central nervous system 94

Sifrol/ Mirapex 94

Overview 94

Sales forecast 95

Historically positioned as a market leading treatment for Parkinson's disease 95

Late entry to once-daily market limits sales potential 96

Genitourinary 97

Flomax 97

Overview 97

Sales forecast 98

Market leading BPH treatment 98

Generic erosion delayed by grant of pediatric exclusivity 99

Chapter 8 Appendix 100

R&D pipeline 100

References 101

Abbreviations 101

Exchange rates 103

About Datamonitor 104

About Datamonitor Healthcare 104

Datamonitor consulting 104

Disclaimer 106

LIST OF TABLES

Table 1: Boehringer Ingelheim - PharmaVitae forecasts at a glance 8

Table 2: Boehringer Ingelheim key product developments, Q1-Q3 2009 23

Table 3: Boehringer Ingelheim product deals and alliances, Q1-Q3 2009 25

Table 4: Boehringer Ingelheim technology deals and alliances, Q1-Q3 2009 26

Table 5: Boehringer Ingelheim M&A activity, Q1-Q3 2009 26

Table 6: Boehringer Ingelheim company announcements, Q1-Q3 2009 27

Table 7: Boehringer Ingelheim future product milestones, 2009-11 28

Table 8: Boehringer Ingelheim's major consumer health care products 33

Table 9: Boehringer Ingelheim product portfolio overview ($m), 2002-08 39

Table 10: Boehringer Ingelheim product portfolio overview ($m), 2008-14 42

Table 11: Boehringer Ingelheim prescription pharmaceutical sales by therapy area ($m), 2008-14 50

Table 12: Boehringer Ingelheim prescription pharmaceutical sales by geographic region ($m), 2008-14 53

Table 13: Boehringer Ingelheim launch portfolio overview ($m), 2008-14 55

Table 14: Boehringer Ingelheim core portfolio overview ($m), 2008-14 58

Table 15: Boehringer Ingelheim expiry portfolio overview ($m), 2008-14 59

Table 16: Boehringer Ingelheim generics portfolio overview ($m), 2008-14 61

Table 17: Boehringer Ingelheim prescription pharmaceutical sales by molecule type ($m), 2008-14 66

Table 18: Boehringer Ingelheim prescription pharmaceutical sales by source ($m), 2008-14 69

Table 19: Total Boehringer Ingelheim sales by business unit ($m), 2002-08 71

Table 20: Boehringer Ingelheim operating revenue/cost analysis ($m), 2002-08 74

Table 21: Boehringer Ingelheim operating cost ratio analysis (% of total revenues), 2002-08 75

Table 22: Key products overview 78

Table 23: Spiriva: overview 79

Table 24: Spiriva: sales forecast ($m), 2008-14 80

Table 25: Micardis: overview 84

Table 26: Micardis franchise: sales forecast ($m), 2008-14 85

Table 27: Pradaxa: overview 88

Table 28: Pradaxa: sales forecast ($m), 2008-14 89

Table 29: Ondero: overview 92

Table 30: Ondero: sales forecast ($m), 2008-14 93

Table 31: Sifrol: overview 94

Table 32: Sifrol franchise: sales forecast ($m), 2008-14 95

Table 33: Flomax: overview 97

Table 34: Flomax: sales forecast ($m), 2008-14 98

Table 35: Boehringer Ingelheim's R&D pipeline (Phase I-registration) 100

Table 36: Exchange rates, 2009 103

List of Figures

Figure 1: The PharmaVitae Explorer 3

Figure 2: Boehringer Ingelheim prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 6

Figure 3: Boehringer Ingelheim's financial performance ($m), 2002-14 7

Figure 4: Boehringer Ingelheim prescription pharmaceutical sales by therapy area ($m), 2002-14 9

Figure 5: Boehringer Ingelheim prescription pharmaceutical sales by product category ($m), 2002-14 11

Figure 6: Boehringer Ingelheim SWOT analysis 14

Figure 7: Boehringer Ingelheim, current corporate structure 31

Figure 8: Boehringer Ingelheim, corporate structure by total net sales ($m), 2002-08 32

Figure 9: Boehringer Ingelheim prescription pharmaceutical performance, sales ($m) and growth rate (%), 2002-14 36

Figure 10: Key product sales ($m), 2002-14 38

Figure 11: Boehringer Ingelheim key sales growth drivers and resistors ($m), 2002-08 40

Figure 12: Boehringer Ingelheim key sales growth drivers and resistors ($m), 2008-14 44

Figure 13: Boehringer Ingelheim prescription pharmaceutical sales by therapy area ($m), 2002-14 47

Figure 14: Boehringer Ingelheim prescription pharmaceutical sales by geographic region ($m), 2002-14 51

Figure 15: Boehringer Ingelheim launch/core/expiry configuration ($m), 2008-14 62

Figure 16: Boehringer Ingelheim prescription pharmaceutical sales by molecule type ($m), 2002-14 64

Figure 17: Boehringer Ingelheim prescription pharmaceutical sales by source ($m), 2002-14 67

Figure 18: Boehringer Ingelheim operating revenue/cost analysis ($m), 2002-08 73

To order this report:

Pharmaceutical Industry: Boehringer Ingelheim GmbH: PharmaVitae Profile

More Market Research Report


    Nicolas Bombourg
    Reportlinker
    Email: nbo@reportlinker.com
    US: (805)652-2626
    Intl: +1 805-652-2626

SOURCE Reportlinker


'/>"/>
SOURCE Reportlinker
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Reportlinker Adds Top Ten Worlds Leading Orthopedics Companies
2. Reportlinker Adds The Future of HIV Therapeutics - Market Forecasts to 2015, Competitive Benchmarking, Product Pipeline and Deals Analysis
3. Reportlinker Adds Medical Fiber Optics - A World Market Analysis
4. Reportlinker Adds Bulk Paclitaxel - A Global Update of Market Trends & Opportunities
5. Reportlinker Adds US Home Healthcare Equipment & Services Market: An Analysis
6. Reportlinker Adds Trauma Devices - Trends & Opportunities Worldwide
7. Reportlinker Adds South Korean Market for Dental Implants and Final Abutments 2009
8. Reportlinker Adds European Markets for Drug Eluting and Bare Metal Stents 2009 (15 Countries)
9. Reportlinker Adds Prepackaged Medical Kits and Trays - A World Market Analysis
10. Reportlinker Adds Cardiac Biomarkers - A Global Market Perspective
11. Reportlinker Adds Radiopharmaceuticals - A US and European Market Analysis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... Inc. (NASDAQ: IONS ), the leader in antisense therapeutics, ... BMO Capital Markets Prescriptions for Success Healthcare Conference on Wednesday, December ... A live webcast of the presentation will be available on the ... be available within 48 hours and will be archived for a ... , , ...
(Date:12/7/2016)... Inc. (NYSE: LCI ) today announced that the company ... Healthcare Conference on December 14, 2016 at 9:20 a.m. (ET) at ... . In addition, the company will host one-on-one meetings ... Annual Boston Healthcare Conference taking place on December 13, 2016 at ... , ...
(Date:12/6/2016)... 2016  Alopexx Oncology, LLC announced data from a ... protein (immunocytokine) composed of interleukin-2 and a CD20-targeting monoclonal ... B cells as Rituxan and maintains the activities of ... involved in tumor targeting, engagement of the immune system, ... of the study (abstract #95954) were presented at the ...
Breaking Medicine Technology:
(Date:12/7/2016)... ... December 07, 2016 , ... Levels of a protein in the blood associated ... appearing online in the journal Radiology. , Heart disease and brain disease exact a ... the rapidly aging population. Damage to both organs often occurs at a subclinical stage, ...
(Date:12/7/2016)... ... December 07, 2016 , ... ODU, a worldwide ... US market its advanced highly customizable contact technology solutions. , ODU Single Contact ... technologies are ideal for a wide range of applications that require customization from ...
(Date:12/7/2016)... , ... December 07, 2016 , ... ... and financial planning services to families and business owners in the greater Dallas ... behalf of the Dallas Fallen Officer Foundation. , Established in 2009 by active ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, ... families throughout the Five Boroughs, is launching a charity drive to raise funds that ... the traditions and spirit of marines and Navy FMF Corpsmen. Working closely with the ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Honolulu cosmetic ... redesigned website, which launched October 17, 2016, features comprehensive information regarding a wide ... layout. Visitors and patients can discover the latest clinical dermatology treatments for medical ...
Breaking Medicine News(10 mins):